Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 7:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,657 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia; Psychosis Clear all
Completed Phase 1 Interventional

Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia

NCT02202226
View directory record Official record
Conditions
Schizophrenia
Interventions
Lu AF35700, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 3 Interventional

A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.

NCT00111189
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Paliperidone Palmitate
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
18
States / cities
Little Rock, Arkansas • Cerritos, California • Santa Ana, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of a Nicotinic Agonist in Schizophrenia

NCT00100165
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, 3-(2,4 dimethoxybenzylidene anabaseine) 150 mg, 3-(2,4 dimethoxybenzylidene anabaseine) 75 mg
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 7, 2026, 7:55 PM EDT
Enrolling by invitation Not applicable Interventional

Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization

NCT07130500
View directory record Official record
Conditions
Schizophrenia Disorder, Schizoaffective Disorder, Bipolar Disorder (BD), Substance Use Disorder (SUD)
Interventions
Financial incentives for adherence to long-acting injectable medication, Standard of care with monthly surveys
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

TDCS for Auditory Hallucinations in Schizophrenia

NCT01898299
View directory record Official record
Conditions
Schizophrenia
Interventions
transcranial Direct Current Stimulation (tDCS), Sham tDCS
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pharmacogenetics of Cannabinoid Response

NCT00678730
View directory record Official record
Conditions
COMT Gene Polymorphism
Interventions
delta 9 tetrahydrocannabinol
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.

NCT02876900
View directory record Official record
Conditions
Schizophrenia
Interventions
Low Dose Asenapine maleate transdermal patch, High Dose Asenapine maleate transdermal patch, Placebo
Drug
Lead sponsor
Noven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Jersey City, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 7, 2026, 7:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder - 2

NCT00135772
View directory record Official record
Conditions
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Not applicable Interventional Results available

Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia

NCT02069392
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cognitive remediation training, Nicotine polacrilex lozenge
Behavioral · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 1 Interventional

A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone

NCT02019329
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, RO5545965, risperidone
Other · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 3 Interventional Results available

A Physical Dependence Study in Schizophrenia

NCT01452919
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, Placebo
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Oakland, California • San Diego, California • Torrance, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dyad Oxytocin Study (DOS)

NCT02302209
View directory record Official record
Conditions
Schizophrenia, Autism Spectrum Disorder
Interventions
Oxytocin, Placebo Comparator
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 7, 2026, 7:55 PM EDT
Not yet recruiting Not applicable Interventional

Optimizing CBSST With Executive Function Training for Schizophrenia (R33)

NCT07658391
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
E-CBSST, E-SC
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
60 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
San Diego, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 7, 2026, 7:55 PM EDT
Recruiting Phase 3 Interventional

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

NCT07114874
View directory record Official record
Conditions
Schizophrenia
Interventions
NBI-1117568
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
50
States / cities
Bryant, Arkansas • Little Rock, Arkansas • Cerritos, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Not applicable Interventional

Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia

NCT00434980
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Family-Directed Cognitive Adaptation Program
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of CAD-9303 in Subjects With Schizophrenia

NCT04306146
View directory record Official record
Conditions
Schizophrenia
Interventions
CAD-9303, Placebos
Drug
Lead sponsor
Cadent Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Long Beach, California • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 2 Interventional

New Drugs in the Treatment of Mood Disorders

NCT00001482
View directory record Official record
Conditions
Anxiety Disorder, Mood Disorder, Psychotic Disorder
Interventions
Lamotrigine (Lamictal® (Registered Trademark), Gabapentin (Neurontin® (Registered Trademark))
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pfizer/IVGTT/Ziprasidone/Olanzapine

NCT00205725
View directory record Official record
Conditions
Schizophrenia, Type 2 Diabetes Mellitus
Interventions
Ziprasidone, Olanzapine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 7, 2026, 7:55 PM EDT
Terminated Phase 3 Interventional Results available

Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia

NCT03593213
View directory record Official record
Conditions
Schizophrenia
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 64 Years
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
42
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 3 Interventional

Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)

NCT00001768
View directory record Official record
Conditions
Autoimmune Diseases, Mental Disorders Diagnosed in Childhood, Schizophrenia
Interventions
Intravenous immunoglobulin
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 7, 2026, 7:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neuroimaging of Dopamine Metabolism in Normal and Psychiatric Patients

NCT00001320
View directory record Official record
Conditions
Healthy, Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability Study of Drug to Treat Schizophrenia

NCT00044005
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone 20 mg, Lurasidone 40 mg, Lurasidone 80mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
26
States / cities
Birmingham, Alabama • Cerritos, California • Garden Grove, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 7, 2026, 7:55 PM EDT
Terminated Not applicable Interventional Results available

Adapting Critical Time Intervention to Support Inpatient Medical Care Transition

NCT03637296
View directory record Official record
Conditions
Schizophrenia, Medical Complication
Interventions
Critical time intervention
Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Not applicable Interventional Results available

Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia

NCT00793780
View directory record Official record
Conditions
Obesity, Schizophrenia, Schizoaffective Disorder
Interventions
Naltrexone 25mg, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 7, 2026, 7:55 PM EDT